409 related articles for article (PubMed ID: 20428688)
21. Anti-parasitic effect of vitamin C alone and in combination with benznidazole against Trypanosoma cruzi.
Puente V; Demaria A; Frank FM; Batlle A; Lombardo ME
PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006764. PubMed ID: 30240395
[TBL] [Abstract][Full Text] [Related]
22. In vitro and in vivo antiparasitic activity of Physalis angulata L. concentrated ethanolic extract against Trypanosoma cruzi.
Meira CS; Guimarães ET; Dos Santos JA; Moreira DR; Nogueira RC; Tomassini TC; Ribeiro IM; de Souza CV; Ribeiro Dos Santos R; Soares MB
Phytomedicine; 2015 Oct; 22(11):969-74. PubMed ID: 26407938
[TBL] [Abstract][Full Text] [Related]
23. First century of Chagas' disease: an overview on novel approaches to nifurtimox and benzonidazole delivery systems.
Salomon CJ
J Pharm Sci; 2012 Mar; 101(3):888-94. PubMed ID: 22161779
[TBL] [Abstract][Full Text] [Related]
24. Ergosterol biosynthesis and drug development for Chagas disease.
Urbina JA
Mem Inst Oswaldo Cruz; 2009 Jul; 104 Suppl 1():311-8. PubMed ID: 19753490
[TBL] [Abstract][Full Text] [Related]
25. Design and synthesis of new 1,2,3-triazoles derived from eugenol and analogues with in vitro and in vivo activity against Trypanosoma cruzi.
Reis RCFM; Dos Santos EG; Benedetti MD; Reis ACC; Brandão GC; Silva GND; Diniz LA; Ferreira RS; Caldas IS; Braga SFP; Souza TB
Eur J Med Chem; 2023 Oct; 258():115622. PubMed ID: 37441850
[TBL] [Abstract][Full Text] [Related]
26. Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives.
Urbina JA
J Eukaryot Microbiol; 2015; 62(1):149-56. PubMed ID: 25284065
[TBL] [Abstract][Full Text] [Related]
27. Trypanocidal activity and selectivity in vitro of aromatic amidine compounds upon bloodstream and intracellular forms of Trypanosoma cruzi.
De Souza EM; da Silva PB; Nefertiti AS; Ismail MA; Arafa RK; Tao B; Nixon-Smith CK; Boykin DW; Soeiro MN
Exp Parasitol; 2011 Feb; 127(2):429-35. PubMed ID: 20971106
[TBL] [Abstract][Full Text] [Related]
28. Challenges in Chagas Disease Drug Discovery: A Review.
Paucar R; Moreno-Viguri E; Pérez-Silanes S
Curr Med Chem; 2016; 23(28):3154-3170. PubMed ID: 27356544
[TBL] [Abstract][Full Text] [Related]
29. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.
Garcia S; Ramos CO; Senra JF; Vilas-Boas F; Rodrigues MM; Campos-de-Carvalho AC; Ribeiro-Dos-Santos R; Soares MB
Antimicrob Agents Chemother; 2005 Apr; 49(4):1521-8. PubMed ID: 15793134
[TBL] [Abstract][Full Text] [Related]
30. An in vitro iron superoxide dismutase inhibitor decreases the parasitemia levels of Trypanosoma cruzi in BALB/c mouse model during acute phase.
Olmo F; Urbanová K; Rosales MJ; Martín-Escolano R; Sánchez-Moreno M; Marín C
Int J Parasitol Drugs Drug Resist; 2015 Dec; 5(3):110-6. PubMed ID: 26236582
[TBL] [Abstract][Full Text] [Related]
31. Novel drug discovery for Chagas disease.
Moraes CB; Franco CH
Expert Opin Drug Discov; 2016; 11(5):447-55. PubMed ID: 26967915
[TBL] [Abstract][Full Text] [Related]
32. Current drug therapy and pharmaceutical challenges for Chagas disease.
Bermudez J; Davies C; Simonazzi A; Real JP; Palma S
Acta Trop; 2016 Apr; 156():1-16. PubMed ID: 26747009
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
Martín-Escolano R; Marín C; Vega M; Martin-Montes Á; Medina-Carmona E; López C; Rotger C; Costa A; Sánchez-Moreno M
Bioorg Med Chem; 2019 Mar; 27(5):865-879. PubMed ID: 30728107
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo biological effects of novel arylimidamide derivatives against Trypanosoma cruzi.
Timm BL; da Silva PB; Batista MM; da Silva FH; da Silva CF; Tidwell RR; Patrick DA; Jones SK; Bakunov SA; Bakunova SM; Soeiro Mde N
Antimicrob Agents Chemother; 2014 Jul; 58(7):3720-6. PubMed ID: 24752263
[TBL] [Abstract][Full Text] [Related]
35. Low-dose benznidazole treatment results in parasite clearance and attenuates heart inflammatory reaction in an experimental model of infection with a highly virulent Trypanosoma cruzi strain.
Cevey ÁC; Mirkin GA; Penas FN; Goren NB
Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):12-22. PubMed ID: 26862474
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo antiproliferative and trypanocidal activities of ruthenium NO donors.
Silva JJ; Osakabe AL; Pavanelli WR; Silva JS; Franco DW
Br J Pharmacol; 2007 Sep; 152(1):112-21. PubMed ID: 17603548
[TBL] [Abstract][Full Text] [Related]
37. An insight on targets and patented drugs for chemotherapy of Chagas disease.
Duschak VG; Couto AS
Recent Pat Antiinfect Drug Discov; 2007 Jan; 2(1):19-51. PubMed ID: 18221162
[TBL] [Abstract][Full Text] [Related]
38. Chagas disease: Present status of pathogenic mechanisms and chemotherapy.
Maya JD; Orellana M; Ferreira J; Kemmerling U; López-Muñoz R; Morello A
Biol Res; 2010; 43(3):323-31. PubMed ID: 21249304
[TBL] [Abstract][Full Text] [Related]
39. Benznidazole, itraconazole and their combination in the treatment of acute experimental chagas disease in dogs.
Cunha ELA; Torchelsen FKVDS; Cunha LM; de Oliveira MT; Fonseca KDS; Vieira PMA; Carneiro CM; de Lana M
Exp Parasitol; 2019 Sep; 204():107711. PubMed ID: 31254494
[TBL] [Abstract][Full Text] [Related]
40. The in vivo trypanocidal effect of the diterpene 5-epi-icetexone obtained from Salvia gilliesii.
Lozano E; Strauss M; Spina R; Cifuente D; Tonn C; Rivarola HW; Sosa MA
Parasitol Int; 2016 Feb; 65(1):23-26. PubMed ID: 26341064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
